ALD-101

Phase 3Biologic

AAldagen

ALD-101 is one of 14 biologic programs targeting Blood Transfusion. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood TransfusionActive, not recruiting

Blood TransfusionPhase 3

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Blood Transfusion

#DrugCompanyPhaseTrials

Cyklokapron

AAmring

Approved

6 2

Desferal

Alnylam Pharmaceuticals

Phase 3

1 3

Ferinject

VVifor Pharma

Approved

1 4

Exjade

Novartis

Phase 2

1 5

ICL670

Novartis

Phase 3

1 6

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

4 7

ALD-101

AAldagen

Phase 3

1 8

Iron Sulphate

PPierre Fabre Pharma GmbH

Phase 1

1 9

Umbilical Cord Blood Unit

WWeill Medical College of Cornell University

Phase 2

1 10

ASD CB-MNC Injection.

SState-Financed Health Facility "Samara Regional Medical Center Dinasty"

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Blood Transfusion1 trial

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

Terminated·AAldagen·Phase 3·NCT00654433·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALD-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALD-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALD-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aldagen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: AAldagen

ALD-101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Blood Transfusion1 trial

References

Drug Info

Quick Facts

Related News